Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting
Intensity Therapeutics announced that first-in-human Cohort A data from the Phase 2 INVINCIBLE-4 study will be presented at ESMO 2026, showing pathological complete response in 5 of 7 patients (71%) treated with INT230-6 plus standard-of-care neoadjuvant immuno-chemotherapy for early-stage triple-negative breast cancer. No invasive breast cancer cells were detected in axillary lymph nodes in 6 of 7 patients despite 71% being initially biopsy-proven node-positive, and all 7 patients showed tumor necrosis after just 1-2 intratumoral injections. Dose-limiting local skin reactions were observed, prompting a protocol amendment to lower injection volume; other adverse events were low grade.
Key figures
- Drug Name
- INT230-6
- Phase Of Trial
- Phase 2
- Cohort
- INVINCIBLE-4 Cohort A (INT230-6 + standard-of-care NAIC)
- Pcr ci
- 95% CI 29-96%
- Pcr rate
- 71%
- Partial response
- 43%
- Patients evaluated
- 7
- Radiological complete response
- 57%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.